



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Fluorescein-12-dATP

Item No. 36233

Formal Name: 4(or 5)-((6-((3-(4-amino-7-((2R,4S,5R)-4-hydroxy-5-(((hydroxy((hydroxy(phosphono oxy)phosphoryl)oxy)phosphoryl)oxy)methyl) tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-yn-1-yl)amino)-6-oxohexyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid

Synonym: Fluorescein-12-2'-deoxyadenosine-5'-triphosphate

MF: C₄₁H₄₁N₆O₁₉P₃

FW: 1,014.7


Purity: ≥95%

Ex./Em. Max: 498/517 nm

Supplied as: A solution in tris buffer, pH 7.5

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fluorescein-12-dATP is supplied as a solution in tris buffer, pH 7.5. Fluorescein-12-dATP is soluble in water.

Description

Fluorescein-12-dATP is a fluorescently labeled form of the nucleotide 2'-deoxyadenosine-5'-triphosphate (dATP; Item No. 32566). It displays excitation/emission maxima of 498/517 nm, respectively. Fluorescein-12-dATP has been used to label DNA in fluorescence *in situ* hybridization (FISH) and nicking enzyme-assisted viewing and sequencing (NicE-viewSeq) applications.^{1,2}

References

1. Estève, P.-O., Vishnu, U.S., Chin, H.G., *et al.* Visualization and sequencing of accessible chromatin reveals cell cycle and PostHDAC inhibitor treatment dynamics. *J. Mol. Biol.* **432(19)**, 5304-5321 (2020).
2. Kasahara, K., Taguchi, T., Yamasaki, I., *et al.* Genetic alterations in prostate cancer. *Handbook of Immunohistochemistry and in situ hybridization of human carcinomas, Volume 2: Molecular pathology, colorectal carcinoma, and prostate carcinoma.* Hayat, M., editor, 1st edition, Elsevier Academic Press (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM